agn-195183
Small moleculeexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2005 (NCT00234169)
Timeline
Indications
Mechanism of action
- Retinoic acid receptor alphaAGONIST
RARA agonist
Not updated trial information since May 2008, discontinued?
Chemistry & pharmacology
Loading structure…
SMILES
CC1(C)CCC(C)(C)c2c1cc(C(=O)Nc1cc(F)c(C(=O)O)c(F)c1)c(O)c2Cl- Mol. weight
- 437.87 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL107430 ↗
Also known as
- agn-195183
- agn-195183
- irx5183
- irx-5183
- irx-5183
- nrx195183
- nrx195183
- nrx 195183
- nrx 195183
- nrx-195183
- nrx-195183
- vtp195183
- vtp-195183
- vtp-195183
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02749708 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | Johns Hopkins University |
| NCT00670150 | Phase 2 | May 1, 2010 | University of Southern California |
| NCT00675870 | Phase 2 | Apr 1, 2008 | NuRx Pharmaceuticals, Inc. |
| NCT00234169 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2005 | Peter MacCallum Cancer Centre, The Leukemia and Lymphoma Society |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| NuRx Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2008 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2005 |
| The Leukemia and Lymphoma Society | Academic/Hospital | 1 | 0 | 1 | 2005 |
| University of Southern California | Academic/Hospital | 1 | 1 | 1 | 2010 |
5 organizations
Page 1 / 1